glp-1 drugs insurance coverage What Is Prior Authorization for GLP-1s? CMS Issues Coverage Guidance on
Description
But "rare" is not "impossible," and you should understand that you are operating in a legal gray area
One of the most consequential changes in 2026 is the loss of exclusivity for semaglutide, beginning in early 2026 across major markets including India, China, Brazil, Turkey and Canada, with semaglutide having lost exclusivity in India on 20th March 2026
Key research domains include: Weight Loss and Adiposity Reduction: Study its role in promoting profound fat loss through combined activation of GLP-1 (satiety), GIP (fat storage modulation), and Glucagon (thermogenesis and lipolysis)
A study that would be very challenging to run (controlled fixed diet - with and without GLP1)
Several small-scale human studies have begun to explore these findings in clinical populations
GIP, a sister incretin hormone to GLP-1, also plays a role in glucose homeostasis
